This content is only available within our institutional offering.
11 Dec 2018
Lighting up the Lungs
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Lighting up the Lungs
Polarean Imaging Plc (POLX:LON) | 3.9 0 0.0% | Mkt Cap: 8.43m
- Published:
11 Dec 2018 -
Author:
Dr. Navid Malik -
Pages:
37
Polarean Imaging Plc is a US-based drug/device company developing a latestage breakthrough imaging technology that was originally developed by General Electric (GE). This technology is based on combining hyperpolarized Xenon with Magnetic Resonance Imaging (MRI) and facilitates the diagnosis of pulmonary (lung) disease, accurately providing both structural and functional data, in an organ where previously it was impossible to garner this information. Pulmonary disease is a market where patient and cost headwinds are growing, predominantly because of a lack of correct and timely diagnosis. In the US, the market opportunity is to help alleviate around US$150bn of cost and assist in the prevention and treatment of lethal diseases such as COPD (bronchitis), the fourth largest cause of death (6% globally). Polarean has begun conducting a relatively low risk (noninferiority) Phase III pivotal trial, aiming to recruit just 80 patients with final data expected in H1 2019. BUY.